Aquestive Q3 revenue beats; raises 2023 guidance to $47-50M; net loss narrows to $2.0M

Aquestive Therapeutics, Inc.

2023-Q3 EPS reported $0.00 revenue$37,377,000

Total Q3 revenue $13.0M vs $11.5M YoY; adjusted for Sympazan out-license, revenue up 42% to $13.0M from $9.2M.
Net loss narrowed to $2.0M ($0.03/share) from $12.5M ($0.23/share); non-GAAP adjusted EBITDA loss improved to $1.3M from $7.7M.
Full-year 2023 revenue guidance raised to $47-50M (prior $44-48M); non-GAAP adjusted EBITDA loss guidance improved to $14-17M (prior $19-22M).
Issued $45M 13.5% Senior Secured Notes due 2028, redeeming prior 12.5% notes, resulting in ~$28M cash savings through June 2025.
Anaphylm pivotal PK study on track for Q4 2023 start with topline data Q1 2024; Libervant NDA for ages 2-5 has PDUFA date April 28, 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aquestive Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).

Period: the third quarter ended September 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On November 6, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the third quarter ended September 30, 2023

View on SEC.gov

Browse all earnings releases →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.